Dataset Information

The transcription factors regulated upstream of the IFI44L gene were screened by DNA pull-down, mass spectrometry combined with bioinformatics methods

ABSTRACT: Proteins bound to the IFI44L promoter were screened through DNA pull-down and mass spectrometry, and further proteins with transcriptional functions were screened through bioinformatics.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: 媛王

LAB HEAD: Jie Dang

PROVIDER: PXD065618 | Pride | 2026-02-09

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	2.Ident_Quantify.zip	Other
	20210719_PB1_21050030_dui1.wiff	Wiff
	20210719_PB1_21050030_dui1.wiff.scan	Wiff
	20210719_PB1_21050030_dui2.wiff	Wiff
	20210719_PB1_21050030_dui2.wiff.scan	Wiff

Items per page:

1 - 5 of 10

Publications

Regulatory dynamics of <i>IFI44L</i> in systemic lupus erythematosus: the interplay of type I interferon and c-Jun.

Wang Yuan Y Yang Mengyi M Ma Hua H Ma Xiuhui X Huo Zhenghao Z Ma Zhanbing Z Dang Jie J

Lupus science & medicine 20260127 1

<h4>Objective</h4>SLE is a multifaceted chronic inflammatory disorder characterised by a dysregulated immune response that involves various organ systems, with significant implications stemming from the type I interferon (IFN) signalling pathway in its pathogenesis. This study aimed to elucidate the contributory role of the IFN-induced protein 44-like (<i>IFI44L</i>) gene in SLE progression and to investigate its transcriptional regulatory mechanisms.<h4>Methods</h4>We quantified <i>IFI44L</i> e ...[more]

PMID: 41592906

Similar Datasets

Project description:BackgroundRecent studies have shown that long non-coding RNAs (lncRNAs) may play key regulatory roles in many malignant tumors. This study investigated the use of novel lncRNA biomarkers in the diagnosis and prognosis of breast cancer.Materials and methodsThe database subsets of The Cancer Genome Atlas (TCGA) by RNA-seq for comparing analysis of tissue samples between breast cancer and normal control groups were downloaded. Additionally, anticoagulant peripheral blood samples were collected and used in this cohort study. The extracellular vesicles (EVs) from the plasma were extracted and sequenced, then analyzed to determine the expressive profiles of the lncRNAs, and the cancer-related differentially expressed lncRNAs were screened out. The expressive profiles and associated downstream-mRNAs were assessed using bioinformatics (such as weighted correlation network analysis (WGCNA), Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genome (KEGG) enrichments, Receiver-Operating Characteristic (ROC) curve and survival analysis, etc.) to investigate the diagnostic and prognostic values of these EV lncRNAs and their effectors.ResultsIn this study, 41 breast cancer-related lncRNAs were screen out from two datasets of tissue and fresh collected plasma samples of breast cancer via the transcriptomic and bioinformatics techniques. A total of 19 gene modules were identified with WGCNA analysis, of which five modules were significantly correlated with the clinical stage of breast cancer, including 28 lncRNA candidates. The ROC curves of these lncRNAs revealed that the area under the curve (AUC) of all candidates were great than 70%. However, eight lncRNAs had an AUC >70%, indicating that the combined one has a good diagnostic value. In addition, the results of survival analysis suggested that two lncRNAs with low expressive levels may indicate the poor prognosis of breast cancer. By tissue sample verification, C15orf54, AL157935.1, LINC01117, and SNHG3 were determined to have good diagnostic ability in breast cancer lesions, however, there was no significant difference in the plasma EVs of patients. Moreover, survival analysis data also showed that AL355974.2 may serve as an independent prognostic factor and as a protective factor.ConclusionA total of five lncRNAs found in this study could be developed as biomarkers for breast cancer patients, including four diagnostic markers (C15orf54, AL157935.1, LINC01117, and SNHG3) and a potential prognostic marker (AL355974.2).